Noncardiac surgery is safe after 6 months after implantation of a DES

Original title: Risk of major adverse cardiac events following noncardiac surgery in patients with coronary stents. Reference: Hawn MT et al. JAMA 2013;DOI:10.1001

In the patients who underwent non cardiac surgery and had coronary angioplasty with stent history  within 2 years there was not increased in major cardiac events (MACE ) with the exception of those who were operated on emergency or had advanced heart disease. In contrast those who received angioplasty at least 6 months prior to surgery showed no increased risk of MACE beyond the type of stent used.

Currently guides suggest waiting at least 6 weeks for the case of a conventional stent and a year after a drug-eluting stent (DES) but according to this study, both stents have an increased risk at the beginning and for both stents the risk reaches base at 6 months. This study is a multicenter retrospective analysis ( Veterans Affairs and Centers for Medicare and Medicaid Services) that included 41989 patients. Between 2000 and 2010 patients 124844 patients were treated with stents, of which 22.5 % were undergoing noncardiac surgery within 2 years. For those who underwent surgery within the first 6 weeks after angioplasty MACE rate was 11.6 % for those operated between 6 weeks and 6 months MACE rate was 6.4 %. Between 6 months and a year and between the first year and the second; the MACE rate was 4.2 % and 3.5 % respectively. The risk of events was also different between patients receiving drug-eluting stents versus bare-metal stents (5.1% versus 4.3 % respectively, p < 0.001 ). However on multivariate analysis only admission for emergency surgery , history of stroke within 6 months after surgery and low cardiac index were predictors of MACE. Of course it is a retrospective registry and this is a major limitation of the study.

Conclusion: 

In patients who undergo noncardiac surgery within 2 years of coronary angioplasty with stent we only observed increased risk of events in those with emergency surgery or advanced heart disease but no difference with respect to the type of stent or at the time of the surgery if this was done at least 6 months later. The emphasis of the guidelines on the stent type and surgical time for drug-eluting stents and conventional, should be reevaluated

Medscape

More articles by this author

Prehospital heparin in STEMI: A safe strategy associated with improved early reperfusion

Early reperfusion remains the main prognostic determinant in patients with ST-segment elevation myocardial infarction (STEMI). Although primary percutaneous coronary intervention (PCI) is the treatment...

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Prehospital heparin in STEMI: A safe strategy associated with improved early reperfusion

Early reperfusion remains the main prognostic determinant in patients with ST-segment elevation myocardial infarction (STEMI). Although primary percutaneous coronary intervention (PCI) is the treatment...

SAPIEN 3 TAVI Durability: Ten-Year Follow-Up in Intermediate-Risk Patients

The durability of transcatheter bioprosthetic valves used in TAVI remains one of the key unanswered questions as indications continue to expand toward patients with...

Aneurysm Sac Regression Predicts Better Clinical Outcomes After EVAR?

Aneurysm sac regression following endovascular abdominal aortic aneurysm repair (EVAR) has been proposed as a marker of favorable remodeling and effective aneurysm exclusion. However,...